A New Perspective to Evaluate the Treatment of Rheumatoid Arthritis with Biological Products
Rheumatoid arthritis(RA)is a widespread systemic autoimmune disease characterized by joint immune dysfunction with severe synovitis and joint erosion,which can further lead to progressive disability.At present,the main therapeutic drugs for RA in clinical practice are disease modifying anti rheumatoid drugs(DMARDs)that alleviate the condition,including traditional synthetic DMARDs(csDMARDs),biological DMARDs(bDMARDs),and targeted synthetic DMARDs(tsDMARDs).In addition,non steroidal anti-inflammatory drugs(NSAIDs)and glucocorticoids(GCs)are also included.Among them,bDMARDs and tsD-MARDs have become the absolute mainstay of the RA market,but due to their long usage cycle and some safety issues,it is im-possible to achieve effective and sustained relief,and the phenomenon of relapse often occurs after drug withdrawal,which further limits the clinical application.The article reviewed the research progress on the recurrence of major RA treatment drugs after discon-tinuation in clinical practice,in order to provide an effective theoretical basis and new ideas for the clinical drug cycle and method.
rheumatoid arthritisdisease-modifying anti-rheumatic drugssmall molecule kinase inhibitorsrelapse after drug withdrawal
万方数据
维普
